List view / Grid view
The pharmaceutical industry is searching for novel drug targets that could produce the next generation of ‘first-in-class’ therapeutic agents. The challenge for academia is to identify and translate such targets and to provide starting points and confidence in the underlying science. The aim should be to generate evidence that modulation…
Progress in the understanding of disease mechanisms provides new opportunities to discover molecules that modulate disease. To capitalise on these opportunities, successful lead discovery strategies need to build on insights into how a cellular phenotype or a target contributes to disease biology. Recent advances in induced pluripotent stem cells (iPSCs),…
2 December 2015 | By Victoria White
GBI Research states that the majority of oncology therapeutics are in the early stages of the pipeline, with 2,937 at the Preclinical stage and 1,591 at the discovery stage...
2 December 2015 | By Victoria White
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Centre are to focus on developing new medicines for pancreatic ductal adenocarcinoma...
2 December 2015 | By ProteinSimple
Simple Western™ system for the characterization of post-translational protein modification by the detection of charge isoforms...
1 December 2015 | By Victoria White
Amcure will use the €1.9 million grant to support the initiation of first-in-man studies for the company's lead candidate for the treatment of epithelial tumours...
30 November 2015 | By Victoria White
Heptares and Pfizer have announced they are to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas...
30 November 2015 | By Victoria White
The aim of the project is to design a drug to inhibit a key parasite enzyme involved in the conversion of blood sugars to energy, to be effective in small doses, even on advanced infections, and kill the parasite...
27 November 2015 | By Victoria White
Researchers have discovered how connections between brain cells are destroyed in the early stages of Alzheimer’s disease...
27 November 2015 | By
Pelago and AstraZeneca will together develop assay formats and applications of the CETSA method relevant across the range of AstraZeneca’s therapeutic areas...
26 November 2015 | By Victoria White
Scientists from the University of Toronto have switched off, one by one, almost 18,000 genes - 90% of the entire human genome - to find the genes that are essential for cell survival...
25 November 2015 | By Victoria White
The transaction, expected to complete next month, is aimed at strengthening ReproCELL’s pharmaceutical industry-targeted drug discovery services...
25 November 2015 | By
Ablynx and Novo Nordisk hope to discover and develop novel multi-specific drug candidates using Ablynx's proprietary Nanobody technology...
22 November 2015 | By Illumina
In this webinar, we focus on the use of microarray technology in drug development...
20 November 2015 | By Victoria White
The company has announced three new partnerships that will deliver a collaborative screening platform, space-age robotics, and sound waves that can move liquids...
